WS #16060
The healthcare sector is emerging as a key defensive play, with AbbVie, Roche, and GSK reporting robust clinical trial data for oncology and lung cancer treatments. AbbVie's ABBV-706 showed a 56% overall response rate in small cell lung cancer, while Roche's Divarasib demonstrated superiority over standard of care. These positive catalysts are attracting capital fleeing from high-multiple tech and energy-vulnerable sectors, supporting healthcare valuations.
Healthcare Earnings Catalyst
The healthcare sector is emerging as a key defensive play, with AbbVie, Roche, and GSK reporting robust clinical trial data for oncology and lung cancer treatments. AbbVie's ABBV-706 showed a 56% overall response rate in small cell lung cancer, while Roche's Divarasib demonstrated superiority over standard of care. These positive catalysts are attracting capital fleeing from high-multiple tech and energy-vulnerable sectors, supporting healthcare valuations.